Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab subcutaneous versus placebo in adults with systemic sclerosis-associated interstitial lung disease
CTR20233175Phase 3Active
- Sponsor
- GSK
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of belimumab in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD), systemic sclerosis (SSc), sponsored by GSK. Started Apr 2024; status: active.
02
Drugs
belimumab
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)systemic sclerosis (SSc)
Beyond the preview
Go deeper on CTR20233175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233175.